IPO - Imunon, Inc.

Form Type: S-1

Filing Date: 2025-05-30

Corporate Action: Ipo

Type: New

Accession Number: 000164117225013088

Filing Summary: Imunon, Inc. has filed a registration statement for an initial public offering (IPO) under the Securities Act of 1933 on May 30, 2025. The company is a clinical-stage biotechnology firm focusing on innovative treatments utilizing non-viral DNA technology aimed at various human diseases. The registration statement allows for the sale and resale of up to 22,027,780 shares of common stock, which includes shares from pre-funded warrants and common warrants issued during a recent private placement that closed on May 27, 2025. This transaction involved selling certain warrants and shares at a combined purchase price of $0.45 per share and was part of a strategy to leverage the company's unique product modalities, including TheraPlas® for cancer treatment and PlaCCine® for vaccine development. The company also highlighted that they will not receive any proceeds from the resale of shares by selling securityholders but will bear the costs associated with the registration. Risks associated with the investment including the potential for the company's common stock to be delisted from Nasdaq were also underscored, as they recently failed to meet minimum stockholders' equity requirements. The company is actively seeking compliance to prevent delisting. Approval for future warrant exercises is contingent upon stockholder approval, which is expected to be sought in a meeting by August 25, 2025.

Form Type: S-1/A

Filing Date: 2025-05-19

Corporate Action: Ipo

Type: Update

Accession Number: 000164117225011388

Filing Summary: Imunon, Inc. is filing an amendment to its registration statement under the Securities Act of 1933, mainly regarding an initial public offering. The company proposes to offer up to 16,666,667 shares of Common Stock and accompanying warrants. The public offering price is assumed at $0.48 per share, with the common warrants exercisable upon stockholder approval, which will determine the exercise price adjustments. The expected closing of the offering is anticipated on or about May 30, 2025. The document emphasizes the risks associated with investing in the company's securities, including potential delisting from Nasdaq, and the need for stockholder approval to enable common warrants' exercise. It also notes that failure to acquire requisite stockholder approval will keep the common warrants unexercisable. Various terms of the securities offering, including the lack of a minimum offering requirement, are detailed, indicating that proceeds may be lower than expected. The document reflects on the company's competitive and regulatory challenges, emphasizing the volatility surrounding its financial future and market engagement.

Form Type: S-1/A

Filing Date: 2025-05-13

Corporate Action: Ipo

Type: Update

Accession Number: 000164117225009814

Filing Summary: Imunon, Inc. is filing an amendment to its S-1 registration statement, indicating a public offering of up to 15,000,000 shares of common stock and associated warrants. This offering is structured as a 'best-efforts' basis with a proposed public offering price of $0.80 per share. The company will also offer common warrants to purchase up to 45,000,000 shares of common stock. Additionally, pre-funded warrants are available for purchasers whose ownership would exceed thresholds of 4.99% or 9.99%. The amendment reveals that the common warrants will only be exercisable after receiving stockholder approval. The initial exercise date of the warrants is contingent on several conditions, including adjustments to the exercise price based on stock performance. If stockholder approval is not obtained, the warrants will not be exercisable, rendering them valueless. The offering aims to raise funds without establishing a minimum requirement, which poses risks of insufficient proceeds for ongoing operations. Imunon's common stock is traded on the Nasdaq under the ticker symbol IMNN, with the last reported price at $0.80 before the filing.

Form Type: S-1

Filing Date: 2025-04-04

Corporate Action: Ipo

Type: New

Accession Number: 000164117225002783

Filing Summary: Imunon, Inc. has filed a registration statement for an initial public offering (IPO) under Form S-1 with the SEC on April 4, 2025. The offering includes up to 10,000,000 shares of common stock, along with common warrants that allow purchasers to buy additional shares. The expected public offering price is set at $1.00 per share based on the last reported sale price on Nasdaq from April 3, 2025. The company has engaged Placement Agents to facilitate the offering, and shares are expected to be issued in a single closing. There is no guaranteed minimum amount of proceeds, which introduces financial risk, and the offering is subject to market conditions. Imunon aims to fund its operations through this IPO while highlighting the uncertainties regarding its financial condition and compliance with Nasdaq listing requirements. The company has noted that substantial doubt exists about its ability to continue as a going concern if it fails to regain compliance with Nasdaq's requirements by May 27, 2025. Investors should assess the high degree of risk associated with investing in this offering, as detailed in the prospectus.

Form Type: DRS

Filing Date: 2025-03-19

Corporate Action: Ipo

Type: New

Accession Number: 000164117225000007

Filing Summary: Imunon, Inc. has submitted a confidential draft registration statement for an initial public offering (IPO) on March 19, 2025, under the Securities Act of 1933. This registration includes details about the proposed offering of shares of common stock and warrants to purchase additional shares. The offering will involve a maximum number of shares and warrants that are yet to be determined, with plans to raise capital through the sale of the securities. Key details about the offering include the structure, lead placement agents, and the contingent nature of the offering based on market reception and regulatory approval. The prospectus underscores potential risks such as compliance with Nasdaq's listing requirements and the company's ability to meet its business objectives. Investors are cautioned that the offering is subject to market conditions, and there is no minimum investment required, posing a risk that the offering could yield fewer proceeds than needed for business goals.